Figure 4. Achievement of expected LDL-C reduction through evolocumab treatment in patients with FH. Blue bars indicate LDL-C reduction following addition of evolocumab to the statin/ezetimibe regimen. Orange bars indicate the achievement of expected LDL-C reduction (adjusted lipid-lowering response) following addition of evolocumab to the statin/ezetimibe regimen. Differences in LDL-C reduction and adjusted response are observed according to mutation type, irrespective of disease homozygosity (From Kim et al.¹⁵⁾).

CNV = copy number variation; FH = familial hypercholesterolemia; HeFH = heterozygous familial hypercholesterolemia; HoFH = homozygous familial hypercholesterolemia; LDL-C = low-density lipoprotein cholesterol.